According to Dolphin stock statistics, as of the close, the share price of Jiuzhou Pharmaceutical was reported at 21.76 yuan, with an increase or decrease of 3.62%, a turnover rate of 1.59%, and a transaction volume of 271 million yuan throughout the day.
01. Fund Interpretation
Today, the stock’s main capital inflow was 67.89 million yuan, with an outflow of 87.78 million yuan, and a net outflow of 19.89 million yuan. Among them, the net outflow for extra-large orders was 6.052 million yuan, the net outflow for large orders was 13.83 million yuan, and the net inflow for medium-sized orders was 13.62 million yuan. , the net inflow of small orders was 6.2673 million yuan.
02. Chip analysis
chip pattern: The current chip pattern of the stock is intensive. In the past 30 days, the chip intensity has increased from 67% to 70%. During the same period, the stock price has risen from 19.72 yuan to 21.76 yuan, an increase of 10.34%.
chip profit and loss: The overall profit-making chips accounted for 84.31%, the average profit was 8.74%, of which light profit-making chips accounted for 15%, heavy profit-making chips accounted for 17%, heavily stuck chips accounted for 0%, and light stuck chips accounted for 1%.
chip cost: the main cost of and is 20.11 yuan, the average cost is 20.18 yuan, the intensive cost of chips is 20.24 yuan, of which 90% of the chips have a highest price of 23.16 yuan and a lowest price of 16.88 yuan, a concentration rate of 84.32%, and the profit ratio of is 79. 49%, 70% of the chips have the highest price of 21.81 yuan and the lowest price of 17.96 yuan, the concentration rate is 90.32%, and the profit ratio is 69.74%.
03. Trading analysis
Dolphin stock APP trading line trend analysis: It is currently in an upward trend, and the short-term trend is stronger than the market. increased in volume and increased in volume, and trading remained active.
04. Texture analysis
The company's main business: The company is a pharmaceutical high-tech enterprise, mainly committed to providing domestic and foreign large and medium-sized pharmaceutical companies with CDMO one-stop services in the research and development and production of innovative drugs; at the same time, it provides global chemical APIs and pharmaceutical intermediates provide business of process technology innovation and commercial production. .
As of December 31, 2019, Jiuzhou Pharmaceutical had operating income of 2.017 billion yuan, and net profit attributable to shareholders of the parent company was 238 million yuan, a year-on-year increase of 51.32%.
No institution has conducted research on Jiuzhou Pharmaceutical in the past three months, and the stock has received relatively low attention from institutions.
Disclaimer: The information provided on this page is for investors' reference only and does not constitute any investment advice.
![Weighted Average Interest Rate in Excel [Sumproduct Function] - DayDayNews](https://i.ytimg.com/vi/WT4f2zL709A/hqdefault.jpg?sqp=-oaymwEcCOADEI4CSFXyq4qpAw4IARUAAIhCGAFwAcABBg==&rs=AOn4CLABH_qZwt7sirHU_3ARF7F1zMVHWw)
